A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Inclusion criteria: * HRPC patients * Evidence of disease progression * Self care, able to perform light work activities * Willing to use contraception throughout the study and for 12 weeks after study completion Exclusion criteria: * History of other cancers not curatively treated with no evidence of disease for more than 5 years. * Prior radiotherapy within 3 weeks of starting study treatment * Prior radiopharmaceuticals (strontium, samarium). * Impaired cardiac function * Heart disease * Liver or renal disease with impaired functions. Other protocol-defined inclusion/exclusion criteria may apply